Literature DB >> 4208920

Modification of NZB-NZW F1 autoimmune disease by development of tolerance to DNA.

L P Parker, B H Hahn, C K Osterland.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4208920

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  7 in total

Review 1.  Suppression of autoimmune diseases with anti-idiotypic antibodies: murine lupus nephritis as a model.

Authors:  B H Hahn
Journal:  Springer Semin Immunopathol       Date:  1984

2.  Distinct clonotypes of anti-DNA antibodies in mice with lupus nephritis.

Authors:  H Yoshida; M Yoshida; S Izui; P H Lambert
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

3.  In vitro nucleoside specific immune response by lymphocytes from systemic lupus erythematosus.

Authors:  C Morimoto; A D Steinberg; S F Schlossman; Y Borel
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

4.  Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus.

Authors:  S Izui; P J McConahey; A N Theofilopoulos; F J Dixon
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

5.  In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA. A possible basis for a local formation of DNA-anti-DNA complexes in systemic lupus erythematosus.

Authors:  S Izui; P H Lambert; P A Miescher
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

6.  Retroviral gp70 immune complexes in NZB x NZW F2 mice with murine lupus nephritis.

Authors:  S Izui; P J McConahey; J P Clark; L M Hang; I Hara; F J Dixon
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

7.  Selective suppression of retroviral gp70-anti-gp70 immune complex formation by prostaglandin E1 in murine systemic lupus erythematosus.

Authors:  S Izui; V E Kelley; P J McConahey; F J Dixon
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.